SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/04/22 AbbVie Inc. 10-Q 6/30/22 74:11M |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 2.78M 2: EX-10.6 Material Contract HTML 72K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 24K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 6: EX-32.2 Certification -- §906 - SOA'02 HTML 22K 12: R1 Document and Entity Information HTML 101K 13: R2 Condensed Consolidated Statements of Earnings HTML 110K (Unaudited) 14: R3 Condensed Consolidated Statements of Comprehensive HTML 61K Income (Unaudited) 15: R4 Condensed Consolidated Statements of Comprehensive HTML 31K Income (Parenthetical) (Unaudited) 16: R5 Condensed Consolidated Balance Sheets HTML 131K 17: R6 Condensed Consolidated Balance Sheets HTML 29K (Parenthetical) 18: R7 Condensed Consolidated Statements of Equity HTML 89K (Unaudited) 19: R8 Condensed Consolidated Statements of Cash Flows HTML 113K (Unaudited) 20: R9 Basis of Presentation HTML 25K 21: R10 Supplemental Financial Information HTML 45K 22: R11 Earnings Per Share HTML 57K 23: R12 Licensing, Acquisitions and Other Arrangements HTML 25K 24: R13 Collaborations HTML 49K 25: R14 Goodwill and Intangible Assets HTML 48K 26: R15 Integration and Restructuring Plans HTML 61K 27: R16 Financial Instruments and Fair Value Measures HTML 198K 28: R17 Post-Employment Benefits HTML 53K 29: R18 Equity HTML 122K 30: R19 Income Taxes HTML 26K 31: R20 Legal Proceedings and Contingencies HTML 42K 32: R21 Segment Information HTML 188K 33: R22 Supplemental Financial Information (Tables) HTML 50K 34: R23 Earnings Per Share (Tables) HTML 56K 35: R24 Collaborations (Tables) HTML 46K 36: R25 Goodwill and Intangible Assets (Tables) HTML 71K 37: R26 Integration and Restructuring Plans (Tables) HTML 66K 38: R27 Financial Instruments and Fair Value Measures HTML 212K (Tables) 39: R28 Post-Employment Benefits (Tables) HTML 53K 40: R29 Equity (Tables) HTML 125K 41: R30 Segment Information (Tables) HTML 183K 42: R31 Basis of Presentation (Details) HTML 24K 43: R32 Supplemental Financial Information (Details) HTML 53K 44: R33 Earnings Per Share (Details) HTML 71K 45: R34 Licensing, Acquisitions and Other Arrangements HTML 44K (Details) 46: R35 Collaborations (Details) HTML 56K 47: R36 Goodwill and Intangible Assets - Goodwill HTML 30K (Details) 48: R37 Goodwill and Intangible Assets - Intangible HTML 45K Assets, Net (Details) 49: R38 Integration and Restructuring Plans (Details) HTML 59K 50: R39 Financial Instruments and Fair Value Measures - HTML 94K Financial Instruments (Details) 51: R40 Financial Instruments and Fair Value Measures - HTML 66K Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) 52: R41 Financial Instruments and Fair Value Measures - HTML 80K Fair Value Measures (Details) 53: R42 Financial Instruments and Fair Value Measures - HTML 52K Significant Level 3 Unobservable Inputs (Details) 54: R43 Financial Instruments and Fair Value Measures - HTML 42K Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) 55: R44 Financial Instruments and Fair Value Measures - HTML 47K Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) 56: R45 Financial Instruments and Fair Value Measures - HTML 34K Concentrations of Risk (Details) 57: R46 Financial Instruments and Fair Value Measures - HTML 56K Debt and Credit Facilities (Details) 58: R47 Post-Employment Benefits (Details) HTML 45K 59: R48 Equity - Stock-Based Compensation (Details) HTML 35K 60: R49 Equity - Stock Options (Details) HTML 31K 61: R50 Equity - RSUs and Performance Shares (Details) HTML 32K 62: R51 Equity - Cash Dividends (Details) HTML 23K 63: R52 Equity - Stock Repurchase Program (Details) HTML 30K 64: R53 Equity - Accumulated Other Comprehensive Loss HTML 66K (Details) 65: R54 Equity - Amounts Reclassified Out Of Accumulated HTML 75K Other Comprehensive Loss (Details) 66: R55 Income Taxes (Details) HTML 27K 67: R56 Legal Proceedings and Contingencies (Details) HTML 62K 68: R57 Segment Information - Additional Information HTML 23K (Details) 69: R58 Segment Information - Disaggregation of Revenue HTML 138K (Details) 72: XML IDEA XML File -- Filing Summary XML 130K 70: XML XBRL Instance -- abbv-20220630_htm XML 3.98M 71: EXCEL IDEA Workbook of Financial Reports XLSX 140K 8: EX-101.CAL XBRL Calculations -- abbv-20220630_cal XML 197K 9: EX-101.DEF XBRL Definitions -- abbv-20220630_def XML 657K 10: EX-101.LAB XBRL Labels -- abbv-20220630_lab XML 1.67M 11: EX-101.PRE XBRL Presentations -- abbv-20220630_pre XML 966K 7: EX-101.SCH XBRL Schema -- abbv-20220630 XSD 154K 73: JSON XBRL Instance as JSON Data -- MetaLinks 420± 635K 74: ZIP XBRL Zipped Folder -- 0001551152-22-000030-xbrl Zip 511K
abbv-20220630 |
(Exact name of registrant as specified in its charter) | ||||||||
i Delaware | i 32-0375147 | |||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification number) |
i Large
Accelerated Filer | ☒ | Accelerated Filer | ☐ | ||||||||
Non-Accelerated Filer | ☐ | Smaller reporting company | i ☐ | ||||||||
Emerging growth company | i ☐ |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
i i Common Stock, par value $0.01 per share / | i i ABBV / | i New York Stock Exchange | ||||||||||||
i Chicago Stock Exchange | ||||||||||||||
i 1.500% Senior Notes due 2023 | i ABBV23B | i New York Stock Exchange | ||||||||||||
i 1.375% Senior Notes due 2024 | i ABBV24 | i New York Stock Exchange | ||||||||||||
i 1.250% Senior Notes due 2024 | i ABBV24B | i New York Stock Exchange | ||||||||||||
i 0.750% Senior Notes due 2027 | i ABBV27 | i New York Stock Exchange | ||||||||||||
i 2.125% Senior Notes due 2028 | i ABBV28 | i New York Stock Exchange | ||||||||||||
i 2.625% Senior Notes due 2028 | i ABBV28B | i New York Stock Exchange | ||||||||||||
i 2.125% Senior Notes due 2029 | i ABBV29 | i New York Stock Exchange | ||||||||||||
i 1.250% Senior Notes due 2031 | i ABBV31 | i New York Stock Exchange |
Page | ||||||||
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Net revenues | $ | i 14,583 | $ | i 13,959 | $ | i 28,121 | $ | i 26,969 | ||||||||||||||||||
Cost of products sold | i 4,170 | i 4,523 | i 8,222 | i 8,736 | ||||||||||||||||||||||
Selling, general and administrative | i 5,412 | i 3,164 | i 8,539 | i 6,006 | ||||||||||||||||||||||
Research and development | i 1,609 | i 1,767 | i 3,106 | i 3,434 | ||||||||||||||||||||||
Acquired IPR&D and milestones | i 269 | i 132 | i 414 | i 317 | ||||||||||||||||||||||
Other operating income | ( i 172) | ( i 68) | ( i 172) | ( i 68) | ||||||||||||||||||||||
Total operating costs and expenses | i 11,288 | i 9,518 | i 20,109 | i 18,425 | ||||||||||||||||||||||
Operating earnings | i 3,295 | i 4,441 | i 8,012 | i 8,544 | ||||||||||||||||||||||
Interest expense, net | i 532 | i 606 | i 1,071 | i 1,228 | ||||||||||||||||||||||
Net foreign exchange loss | i 47 | i 14 | i 72 | i 23 | ||||||||||||||||||||||
Other expense, net | i 1,533 | i 2,658 | i 757 | i 2,263 | ||||||||||||||||||||||
Earnings before income tax expense | i 1,183 | i 1,163 | i 6,112 | i 5,030 | ||||||||||||||||||||||
Income tax expense | i 255 | i 394 | i 691 | i 706 | ||||||||||||||||||||||
Net earnings | i 928 | i 769 | i 5,421 | i 4,324 | ||||||||||||||||||||||
Net earnings attributable to noncontrolling interest | i 4 | i 3 | i 7 | i 5 | ||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 924 | $ | i 766 | $ | i 5,414 | $ | i 4,319 | ||||||||||||||||||
Per share data | ||||||||||||||||||||||||||
Basic earnings per share attributable to AbbVie Inc. | $ | i 0.52 | $ | i 0.42 | $ | i 3.04 | $ | i 2.42 | ||||||||||||||||||
Diluted earnings per share attributable to AbbVie Inc. | $ | i 0.51 | $ | i 0.42 | $ | i 3.03 | $ | i 2.41 | ||||||||||||||||||
Weighted-average basic shares outstanding | i 1,770 | i 1,769 | i 1,770 | i 1,769 | ||||||||||||||||||||||
Weighted-average diluted shares outstanding | i 1,776 | i 1,776 | i 1,777 | i 1,776 |
2022 Form 10-Q | | 1 |
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net earnings | $ | i 928 | $ | i 769 | $ | i 5,421 | $ | i 4,324 | |||||||||||||||
Foreign
currency translation adjustments, net of tax expense (benefit) of $( i 12) for the three months and $( i 19)
for the six months ended June 30, 2022 and $ i 1 for the three months and $( i 24)
for the six months ended June 30, 2021 | ( i 823) | i 244 | ( i 1,054) | ( i 433) | |||||||||||||||||||
Net
investment hedging activities, net of tax expense (benefit) of $ i 146 for the three months and $ i 183 for the six months ended June
30, 2022 and $( i 31) for the three months and $ i 72 for the six months ended June
30, 2021 | i 536 | ( i 114) | i 666 | i 260 | |||||||||||||||||||
Pension
and post-employment benefits, net of tax expense (benefit) of $ i 11 for the three months and $ i 21
for the six months ended June 30, 2022 and $ i 14 for the three months and $ i 33
for the six months ended June 30, 2021 | i 48 | i 50 | i 76 | i 129 | |||||||||||||||||||
Cash
flow hedging activities, net of tax expense (benefit) of $ i 5 for the three months and $ i 3
for the six months ended June 30, 2022 and $ i — for the three months and $ i 3
for the six months ended June 30, 2021 | i 27 | i 12 | i 15 | i 58 | |||||||||||||||||||
Other comprehensive income (loss) | ( i 212) | i 192 | ( i 297) | i 14 | |||||||||||||||||||
Comprehensive income | i 716 | i 961 | i 5,124 | i 4,338 | |||||||||||||||||||
Comprehensive income attributable to noncontrolling interest | i 4 | i 3 | i 7 | i 5 | |||||||||||||||||||
Comprehensive income attributable to AbbVie Inc. | $ | i 712 | $ | i 958 | $ | i 5,117 | $ | i 4,333 |
2022 Form 10-Q | | 2 |
(in millions, except share data) | June 30, 2022 | December 31, 2021 | |||||||||
(unaudited) | |||||||||||
Assets | |||||||||||
Current assets | |||||||||||
Cash and equivalents | $ | i 8,521 | $ | i 9,746 | |||||||
Short-term investments | i 1,440 | i 84 | |||||||||
Accounts receivable, net | i 11,237 | i 9,977 | |||||||||
Inventories | i 3,396 | i 3,128 | |||||||||
Prepaid expenses and other | i 4,506 | i 4,993 | |||||||||
Total current assets | i 29,100 | i 27,928 | |||||||||
Investments | i 244 | i 277 | |||||||||
Property and equipment, net | i 4,958 | i 5,110 | |||||||||
Intangible assets, net | i 71,823 | i 75,951 | |||||||||
Goodwill | i 32,028 | i 32,379 | |||||||||
Other assets | i 5,033 | i 4,884 | |||||||||
Total assets | $ | i 143,186 | $ | i 146,529 | |||||||
Liabilities and Equity | |||||||||||
Current liabilities | |||||||||||
Short-term borrowings | $ | i 17 | $ | i 14 | |||||||
Current portion of long-term debt and finance lease obligations | i 11,913 | i 12,481 | |||||||||
Accounts payable and accrued liabilities | i 22,543 | i 22,699 | |||||||||
Total current liabilities | i 34,473 | i 35,194 | |||||||||
Long-term debt and finance lease obligations | i 61,002 | i 64,189 | |||||||||
Deferred income taxes | i 2,255 | i 3,009 | |||||||||
Other long-term liabilities | i 30,768 | i 28,701 | |||||||||
Commitments and contingencies | i | i | |||||||||
Stockholders' equity | |||||||||||
Common stock, $ i i 0.01 /
par value, i i 4,000,000,000 / shares authorized,
i 1,812,622,099 shares issued as of June 30, 2022 and i 1,803,195,293 as of December 31, 2021 | i 18 | i 18 | |||||||||
Common
stock held in treasury, at cost, i 44,595,448 shares as of June 30, 2022 and i 34,857,597 as of December 31, 2021 | ( i 4,591) | ( i 3,143) | |||||||||
Additional paid-in capital | i 18,906 | i 18,305 | |||||||||
Retained earnings | i 3,516 | i 3,127 | |||||||||
Accumulated other comprehensive loss | ( i 3,196) | ( i 2,899) | |||||||||
Total stockholders' equity | i 14,653 | i 15,408 | |||||||||
Noncontrolling interest | i 35 | i 28 | |||||||||
Total equity | i 14,688 | i 15,436 | |||||||||
Total liabilities and equity | $ | i 143,186 | $ | i 146,529 |
2022 Form 10-Q | | 3 |
(in millions) | Common shares outstanding | Common stock | Treasury stock | Additional paid-in capital | Retained earnings | Accumulated other comprehensive loss | Noncontrolling interest | Total | |||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2021 | i 1,766 | $ | i 18 | $ | ( i 3,017) | $ | i 17,712 | $ | i 2,292 | $ | ( i 3,295) | $ | i 23 | $ | i 13,733 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 766 | i — | i — | i 766 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive income, net of tax | — | i — | i — | i — | i — | i 192 | i — | i 192 | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 2,318) | i — | i — | ( i 2,318) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | i — | i — | ( i 10) | i — | i — | i — | i — | ( i 10) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 1 | i — | i 5 | i 224 | i — | i — | i — | i 229 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 2 | i 2 | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | i 1,767 | $ | i 18 | $ | ( i 3,022) | $ | i 17,936 | $ | i 740 | $ | ( i 3,103) | $ | i 25 | $ | i 12,594 | ||||||||||||||||||||||||||||||||
Balance at March 31, 2022 | i 1,767 | $ | i 18 | $ | ( i 4,585) | $ | i 18,731 | $ | i 5,103 | $ | ( i 2,984) | $ | i 31 | $ | i 16,314 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 924 | i — | i — | i 924 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 212) | i — | ( i 212) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 2,511) | i — | i — | ( i 2,511) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | i — | i — | ( i 9) | i — | i — | i — | i — | ( i 9) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 1 | i — | i 3 | i 175 | i — | i — | i — | i 178 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 4 | i 4 | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2022 | i 1,768 | $ | i 18 | $ | ( i 4,591) | $ | i 18,906 | $ | i 3,516 | $ | ( i 3,196) | $ | i 35 | $ | i 14,688 | ||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | i 1,765 | $ | i 18 | $ | ( i 2,264) | $ | i 17,384 | $ | i 1,055 | $ | ( i 3,117) | $ | i 21 | $ | i 13,097 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 4,319 | i — | i — | i 4,319 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive income, net of tax | — | i — | i — | i — | i — | i 14 | i — | i 14 | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 4,634) | i — | i — | ( i 4,634) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | ( i 7) | i — | ( i 797) | i — | i — | i — | i — | ( i 797) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 9 | i — | i 39 | i 552 | i — | i — | i — | i 591 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 4 | i 4 | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | i 1,767 | $ | i 18 | $ | ( i 3,022) | $ | i 17,936 | $ | i 740 | $ | ( i 3,103) | $ | i 25 | $ | i 12,594 | ||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | i 1,768 | $ | i 18 | $ | ( i 3,143) | $ | i 18,305 | $ | i 3,127 | $ | ( i 2,899) | $ | i 28 | $ | i 15,436 | ||||||||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | — | i — | i — | i — | i 5,414 | i — | i — | i 5,414 | |||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | i — | i — | i — | i — | ( i 297) | i — | ( i 297) | |||||||||||||||||||||||||||||||||||||||
Dividends declared | — | i — | i — | i — | ( i 5,025) | i — | i — | ( i 5,025) | |||||||||||||||||||||||||||||||||||||||
Purchases of treasury stock | ( i 10) | i — | ( i 1,479) | i — | i — | i — | i — | ( i 1,479) | |||||||||||||||||||||||||||||||||||||||
Stock-based compensation plans and other | i 10 | i | i 31 | i 601 | i | i — | i — | i 632 | |||||||||||||||||||||||||||||||||||||||
Change in noncontrolling interest | — | i — | i — | i — | i — | i — | i 7 | i 7 | |||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2022 | i 1,768 | $ | i 18 | $ | ( i 4,591) | $ | i 18,906 | $ | i 3,516 | $ | ( i 3,196) | $ | i 35 | $ | i 14,688 |
2022 Form 10-Q | | 4 |
Six months ended June 30, | |||||||||||
(in millions) (brackets denote cash outflows) | 2022 | 2021 | |||||||||
Cash flows from operating activities | |||||||||||
Net earnings | $ | i 5,421 | $ | i 4,324 | |||||||
Adjustments to reconcile net earnings to net cash from operating activities: | |||||||||||
Depreciation | i 401 | i 407 | |||||||||
Amortization of intangible assets | i 3,704 | i 4,008 | |||||||||
Deferred income taxes | ( i 794) | ( i 119) | |||||||||
Change in fair value of contingent consideration liabilities | i 861 | i 2,349 | |||||||||
Stock-based compensation | i 413 | i 428 | |||||||||
Acquired IPR&D and milestones | i 414 | i 317 | |||||||||
Gain on divestitures | ( i 172) | ( i 68) | |||||||||
Non-cash litigation reserve adjustments, net of cash payments | i 2,190 | i 97 | |||||||||
Other, net | ( i 86) | ( i 30) | |||||||||
Changes in operating assets and liabilities, net of acquisitions: | |||||||||||
Accounts receivable | ( i 1,396) | ( i 1,162) | |||||||||
Inventories | ( i 499) | ( i 249) | |||||||||
Prepaid expenses and other assets | i 14 | ( i 281) | |||||||||
Accounts payable and other liabilities | ( i 448) | i 308 | |||||||||
Income tax assets and liabilities, net | ( i 110) | ( i 562) | |||||||||
Cash flows from operating activities | i 9,913 | i 9,767 | |||||||||
Cash flows from investing activities | |||||||||||
Acquisitions and investments | ( i 394) | ( i 345) | |||||||||
Acquisitions of property and equipment | ( i 305) | ( i 383) | |||||||||
Purchases of investment securities | ( i 1,411) | ( i 56) | |||||||||
Sales and maturities of investment securities | i 50 | i 65 | |||||||||
Other, net | i 599 | i 135 | |||||||||
Cash flows from investing activities | ( i 1,461) | ( i 584) | |||||||||
Cash flows from financing activities | |||||||||||
Proceeds from issuance of long-term debt | i 2,000 | — | |||||||||
Repayments of long-term debt and finance lease obligations | ( i 4,881) | ( i 3,461) | |||||||||
Dividends paid | ( i 5,033) | ( i 4,632) | |||||||||
Purchases of treasury stock | ( i 1,479) | ( i 797) | |||||||||
Proceeds from the exercise of stock options | i 198 | i 144 | |||||||||
Payments of contingent consideration liabilities | ( i 482) | ( i 313) | |||||||||
Other, net | i 26 | i 1 | |||||||||
Cash flows from financing activities | ( i 9,651) | ( i 9,058) | |||||||||
Effect of exchange rate changes on cash and equivalents | ( i 26) | ( i 28) | |||||||||
Net change in cash and equivalents | ( i 1,225) | i 97 | |||||||||
Cash and equivalents, beginning of period | i 9,746 | i 8,449 | |||||||||
Cash and equivalents, end of period | $ | i 8,521 | $ | i 8,546 | |||||||
2022 Form 10-Q | | 5 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Interest expense | $ | i 556 | $ | i 615 | $ | i 1,104 | $ | i 1,247 | ||||||||||||||||||
Interest income | ( i 24) | ( i 9) | ( i 33) | ( i 19) | ||||||||||||||||||||||
Interest expense, net | $ | i 532 | $ | i 606 | $ | i 1,071 | $ | i 1,228 |
(in millions) | June
30, 2022 | December 31, 2021 | |||||||||
Finished goods | $ | i 1,158 | $ | i 932 | |||||||
Work-in-process | i 1,250 | i 1,193 | |||||||||
Raw materials | i 988 | i 1,003 | |||||||||
Inventories | $ | i 3,396 | $ | i 3,128 |
2022
Form 10-Q | | 6 |
(in millions) | June
30, 2022 | December 31, 2021 | |||||||||
Property and equipment, gross | $ | i 10,827 | $ | i 10,727 | |||||||
Accumulated depreciation | ( i 5,869) | ( i 5,617) | |||||||||
Property and equipment, net | $ | i 4,958 | $ | i 5,110 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions, except per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Basic EPS | ||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 924 | $ | i 766 | $ | i 5,414 | $ | i 4,319 | ||||||||||||||||||
Earnings allocated to participating securities | i 11 | i 17 | i 26 | i 34 | ||||||||||||||||||||||
Earnings available to common shareholders | $ | i 913 | $ | i 749 | $ | i 5,388 | $ | i 4,285 | ||||||||||||||||||
Weighted-average basic shares outstanding | i 1,770 | i 1,769 | i 1,770 | i 1,769 | ||||||||||||||||||||||
Basic earnings per share attributable to AbbVie Inc. | $ | i 0.52 | $ | i 0.42 | $ | i 3.04 | $ | i 2.42 | ||||||||||||||||||
Diluted EPS | ||||||||||||||||||||||||||
Net earnings attributable to AbbVie Inc. | $ | i 924 | $ | i 766 | $ | i 5,414 | $ | i 4,319 | ||||||||||||||||||
Earnings allocated to participating securities | i 11 | i 17 | i 26 | i 34 | ||||||||||||||||||||||
Earnings available to common shareholders | $ | i 913 | $ | i 749 | $ | i 5,388 | $ | i 4,285 | ||||||||||||||||||
Weighted-average shares of common stock outstanding | i 1,770 | i 1,769 | i 1,770 | i 1,769 | ||||||||||||||||||||||
Effect of dilutive securities | i 6 | i 7 | i 7 | i 7 | ||||||||||||||||||||||
Weighted-average diluted shares outstanding | i 1,776 | i 1,776 | i 1,777 | i 1,776 | ||||||||||||||||||||||
Diluted earnings per share attributable to AbbVie Inc. | $ | i 0.51 | $ | i 0.42 | $ | i 3.03 | $ | i 2.41 |
2022 Form 10-Q | | 7 |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
United States - Janssen's share of profits (included in cost of products sold) | $ | i 404 | $ | i 514 | $ | i 812 | $ | i 979 | ||||||||||||||||||
International - AbbVie's share of profits (included in net revenues) | i 283 | i 282 | i 582 | i 551 | ||||||||||||||||||||||
Global - AbbVie's share of other costs (included in respective line items) | i 69 | i 74 | i 133 | i 144 |
2022 Form 10-Q | | 8 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Genentech's share of profits, including royalties (included in cost of products sold) | $ | i 196 | $ | i 168 | $ | i 374 | $ | i 327 | ||||||||||||||||||
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) | i 5 | i 8 | i 17 | i 19 | ||||||||||||||||||||||
AbbVie's share of development costs (included in R&D) | i 31 | i 34 | i 58 | i 76 |
(in millions) | |||||
Balance as of December 31, 2021 | $ | i 32,379 | |||
Foreign currency translation adjustments | ( i 351) | ||||
Balance as of June 30, 2022 | $ | i 32,028 |
June 30, 2022 | December 31, 2021 | ||||||||||||||||||||||||||||||||||
(in millions) | Gross carrying amount | Accumulated amortization | Net carrying amount | Gross carrying amount | Accumulated amortization | Net carrying amount | |||||||||||||||||||||||||||||
Definite-lived intangible assets | |||||||||||||||||||||||||||||||||||
Developed product rights | $ | i 88,443 | $ | ( i 21,679) | $ | i 66,764 | $ | i 88,945 | $ | ( i 18,463) | $ | i 70,482 | |||||||||||||||||||||||
License agreements | i 8,487 | ( i 4,098) | i 4,389 | i 8,487 | ( i 3,688) | i 4,799 | |||||||||||||||||||||||||||||
Total definite-lived intangible assets | i 96,930 | ( i 25,777) | i 71,153 | i 97,432 | ( i 22,151) | i 75,281 | |||||||||||||||||||||||||||||
Indefinite-lived intangible assets | i 670 | — | i 670 | i 670 | — | i 670 | |||||||||||||||||||||||||||||
Total intangible assets, net | $ | i 97,600 | $ | ( i 25,777) | $ | i 71,823 | $ | i 98,102 | $ | ( i 22,151) | $ | i 75,951 |
2022 Form 10-Q | | 9 |
Severance and employee benefits | Other integration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three months ended June 30, | Six months ended June 30, | Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cost of products sold | $ | ( i 5) | $ | i — | $ | ( i 4) | $ | i 6 | $ | i 31 | $ | i 25 | $ | i 61 | $ | i 40 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Research and development | ( i 2) | i — | i 1 | i — | i 3 | i 18 | i 9 | i 69 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selling, general and administrative | ( i 4) | i 12 | i — | i 29 | i 80 | i 75 | i 146 | i 125 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total charges (benefits) | $ | ( i 11) | $ | i 12 | $ | ( i 3) | $ | i 35 | $ | i 114 | $ | i 118 | $ | i 216 | $ | i 234 |
(in millions) | Severance and employee benefits | Other integration | |||||||||
Accrued balance as of December 31, 2021 | $ | i 222 | $ | i 33 | |||||||
Charges (benefits) | ( i 3) | i 199 | |||||||||
Payments and other adjustments | ( i 90) | ( i 220) | |||||||||
Accrued balance as of June 30, 2022 | $ | i 129 | $ | i 12 |
(in millions) | |||||
Accrued balance as of December 31, 2021 | $ | i 33 | |||
Restructuring charges | i 72 | ||||
Payments and other adjustments | ( i 13) | ||||
Accrued balance as of June 30, 2022 | $ | i 92 |
2022
Form 10-Q | | 10 |
2022 Form 10-Q | | 11 |
Fair value – Derivatives in asset position | Fair value – Derivatives in liability position | ||||||||||||||||||||||
(in millions) | Balance sheet caption | June 30, 2022 | December 31, 2021 | Balance sheet caption | June 30, 2022 | December 31, 2021 | |||||||||||||||||
Foreign currency forward exchange contracts | |||||||||||||||||||||||
Designated as cash flow hedges | Prepaid expenses and other | $ | i 47 | $ | i 51 | Accounts payable and accrued liabilities | $ | i 5 | $ | i 2 | |||||||||||||
Designated as cash flow hedges | Other assets | i 4 | i — | Other long-term liabilities | i — | i — | |||||||||||||||||
Designated as net investment hedges | Prepaid expenses and other | i 32 | i 149 | Accounts payable and accrued liabilities | i — | i — | |||||||||||||||||
Designated as net investment hedges | Other assets | i 129 | i 15 | Other long-term liabilities | i — | i — | |||||||||||||||||
Not designated as hedges | Prepaid expenses and other | i 22 | i 26 | Accounts payable and accrued liabilities | i 41 | i 13 | |||||||||||||||||
Interest rate swap contracts | |||||||||||||||||||||||
Designated as cash flow hedges | Prepaid expenses and other | i 2 | i — | Accounts payable and accrued liabilities | i — | i 7 | |||||||||||||||||
Designated as fair value hedges | Prepaid expenses and other | i — | i — | Accounts payable and accrued liabilities | i 16 | i — | |||||||||||||||||
Designated as fair value hedges | Other assets | i — | i 26 | Other long-term liabilities | i 256 | i 15 | |||||||||||||||||
Total derivatives | $ | i 236 | $ | i 267 | $ | i 318 | $ | i 37 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Foreign currency forward exchange contracts | ||||||||||||||||||||||||||
Designated as cash flow hedges | $ | i 53 | $ | ( i 11) | $ | i 47 | $ | i 24 | ||||||||||||||||||
Designated as net investment hedges | i 304 | ( i 14) | i 386 | i 85 | ||||||||||||||||||||||
Interest rate swap contracts designated as cash flow hedges | i 2 | i — | i 6 | i 1 | ||||||||||||||||||||||
2022 Form 10-Q | | 12 |
Three
months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||||||||
(in millions) | Statement of earnings caption | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||
Foreign currency forward exchange contracts | |||||||||||||||||||||||||||||
Designated as cash flow hedges | Cost of products sold | $ | i 18 | $ | ( i 22) | $ | i 26 | $ | ( i 34) | ||||||||||||||||||||
Designated as net investment hedges | Interest expense, net | i 24 | i 5 | i 38 | i 9 | ||||||||||||||||||||||||
Not designated as hedges | Net foreign exchange loss | ( i 123) | ( i 3) | ( i 164) | ( i 28) | ||||||||||||||||||||||||
Treasury rate lock agreements designated as cash flow hedges | Interest expense, net | i 6 | i 6 | i 12 | i 12 | ||||||||||||||||||||||||
Interest rate swap contracts | |||||||||||||||||||||||||||||
Designated as cash flow hedges | Interest expense, net | ( i 1) | ( i 7) | ( i 3) | ( i 14) | ||||||||||||||||||||||||
Designated as fair value hedges | Interest expense, net | ( i 99) | ( i 11) | ( i 283) | ( i 68) | ||||||||||||||||||||||||
Debt designated as hedged item in fair value hedges | Interest expense, net | i 99 | i 11 | i 283 | i 68 |
Basis of fair value measurement | |||||||||||||||||||||||
(in millions) | Total | Quoted prices in
active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and equivalents | $ | i 8,521 | $ | i 4,212 | $ | i 4,309 | $ | i — | |||||||||||||||
Money market funds and time deposits | i 1,425 | i — | i 1,425 | i — | |||||||||||||||||||
Debt securities | i 37 | i — | i 37 | i — | |||||||||||||||||||
Equity securities | i 74 | i 54 | i 20 | i — | |||||||||||||||||||
Interest rate swap contracts | i 2 | i — | i 2 | i — | |||||||||||||||||||
Foreign currency contracts | i 234 | i — | i 234 | i — | |||||||||||||||||||
Total assets | $ | i 10,293 | $ | i 4,266 | $ | i 6,027 | $ | i — | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Interest rate swap contracts | $ | i 272 | $ | i — | $ | i 272 | $ | i — | |||||||||||||||
Foreign currency contracts | i 46 | i — | i 46 | i — | |||||||||||||||||||
Contingent consideration | i 15,178 | i — | i — | i 15,178 | |||||||||||||||||||
Total liabilities | $ | i 15,496 | $ | i — | $ | i 318 | $ | i 15,178 |
2022
Form 10-Q | | 13 |
Basis of fair value measurement | |||||||||||||||||||||||
(in millions) | Total | Quoted prices in
active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||
Assets | |||||||||||||||||||||||
Cash and equivalents | $ | i 9,746 | $ | i 4,451 | $ | i 5,295 | $ | i — | |||||||||||||||
Money market funds and time deposits | i 45 | i — | i 45 | i — | |||||||||||||||||||
Debt securities | i 46 | i — | i 46 | i — | |||||||||||||||||||
Equity securities | i 121 | i 100 | i 21 | i — | |||||||||||||||||||
Interest rate swap contracts | i 26 | i — | i 26 | i — | |||||||||||||||||||
Foreign currency contracts | i 241 | i — | i 241 | i — | |||||||||||||||||||
Total assets | $ | i 10,225 | $ | i 4,551 | $ | i 5,674 | $ | i — | |||||||||||||||
Liabilities | |||||||||||||||||||||||
Interest rate swap contracts | $ | i 22 | $ | i — | $ | i 22 | $ | i — | |||||||||||||||
Foreign currency contracts | i 15 | i — | i 15 | i — | |||||||||||||||||||
Contingent consideration | i 14,887 | i — | i — | i 14,887 | |||||||||||||||||||
Total liabilities | $ | i 14,924 | $ | i — | $ | i 37 | $ | i 14,887 |
June 30, 2022 | December 31, 2021 | ||||||||||||||||
(in millions) | Range | Weighted
average(a) | Range | Weighted average(a) | |||||||||||||
Discount rate | i 2.4% - i 4.8% | i 4.1% | i 0.2%-
i 2.6% | i 1.7% | |||||||||||||
Probability of payment for unachieved milestones | i 89% - i 100% | i 95% | i 89%
- i 100% | i 90% | |||||||||||||
Probability
of payment for royalties by indication(b) | i 56% - i 100% | i 99% | i 56%
- i 100% | i 96% | |||||||||||||
Projected year of payments | i 2022 - i 2034 | i 2027 | i 2022
- i 2034 | i 2027 |
2022 Form 10-Q | | 14 |
Six
months ended June 30, | ||||||||||||||
(in millions) | 2022 | 2021 | ||||||||||||
Beginning balance | $ | i 14,887 | $ | i 12,997 | ||||||||||
Change in fair value recognized in net earnings | i 861 | i 2,349 | ||||||||||||
Payments | ( i 570) | ( i 357) | ||||||||||||
Ending balance | $ | i 15,178 | $ | i 14,989 |
Basis of fair value measurement | ||||||||||||||||||||||||||
(in millions) | Book value | Approximate fair value | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Short-term borrowings | $ | i 17 | $ | i 17 | $ | i — | $ | i 17 | $ | i — | ||||||||||||||||
Current portion of long-term debt and finance lease obligations, excluding fair value hedges | i 11,918 | i 11,906 | i 11,549 | i 357 | i — | |||||||||||||||||||||
Long-term debt and finance lease obligations, excluding fair value hedges | i 61,202 | i 57,471 | i 56,674 | i 797 | i — | |||||||||||||||||||||
Total liabilities | $ | i 73,137 | $ | i 69,394 | $ | i 68,223 | $ | i 1,171 | $ | i — |
Basis of fair value measurement | ||||||||||||||||||||||||||
(in millions) | Book value | Approximate fair value | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||||
Short-term borrowings | $ | i 14 | $ | i 14 | $ | i — | $ | i 14 | $ | i — | ||||||||||||||||
Current portion of long-term debt and finance lease obligations, excluding fair value hedges | i 12,455 | i 11,830 | i 11,329 | i 501 | i — | |||||||||||||||||||||
Long-term debt and finance lease obligations, excluding fair value hedges | i 64,113 | i 71,810 | i 70,757 | i 1,053 | i — | |||||||||||||||||||||
Total liabilities | $ | i 76,582 | $ | i 83,654 | $ | i 82,086 | $ | i 1,568 | $ | i — |
2022 Form 10-Q | | 15 |
Defined
benefit plans | Other post- employment plans | ||||||||||||||||||||||||||||||||||||||||||||||
Three months ended June 30, | Six months ended June 30, | Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||
Service cost | $ | i 113 | $ | i 109 | $ | i 229 | $ | i 221 | $ | i 13 | $ | i 12 | $ | i 25 | $ | i 24 | |||||||||||||||||||||||||||||||
Interest cost | i 75 | i 60 | i 149 | i 118 | i 6 | i 4 | i 12 | i 9 | |||||||||||||||||||||||||||||||||||||||
Expected return on plan assets | ( i 179) | ( i 166) | ( i 359) | ( i 332) | i — | i — | i — | i — | |||||||||||||||||||||||||||||||||||||||
Amortization of prior service cost (credit) | i — | i — | i 1 | i 1 | ( i 9) | ( i 9) | ( i 19) | ( i 19) | |||||||||||||||||||||||||||||||||||||||
Amortization of actuarial loss | i 59 | i 75 | i 116 | i 145 | i 6 | i 8 | i 13 | i 16 | |||||||||||||||||||||||||||||||||||||||
Net periodic benefit cost | $ | i 68 | $ | i 78 | $ | i 136 | $ | i 153 | $ | i 16 | $ | i 15 | $ | i 31 | $ | i 30 |
2022 Form 10-Q | | 16 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Cost of products sold | $ | i 6 | $ | i 10 | $ | i 25 | $ | i 30 | ||||||||||||||||||
Research and development | i 40 | i 47 | i 147 | i 134 | ||||||||||||||||||||||
Selling, general and administrative | i 61 | i 102 | i 241 | i 264 | ||||||||||||||||||||||
Pre-tax compensation expense | i 107 | i 159 | i 413 | i 428 | ||||||||||||||||||||||
Tax benefit | i 21 | i 26 | i 77 | i 74 | ||||||||||||||||||||||
After-tax compensation expense | $ | i 86 | $ | i 133 | $ | i 336 | $ | i 354 |
2022 | 2021 | |||||||||||||||||||||||||||||||
Date Declared | Payment Date | Dividend Per Share | Date Declared | Payment Date | Dividend Per Share | |||||||||||||||||||||||||||
06/23/22 | 08/15/22 | $ | i 1.41 | 10/29/21 | 02/15/22 | $ | i 1.41 | |||||||||||||||||||||||||
02/17/22 | 05/16/22 | $ | i 1.41 | 09/10/21 | 11/15/21 | $ | i 1.30 | |||||||||||||||||||||||||
06/17/21 | 08/16/21 | $ | i 1.30 | |||||||||||||||||||||||||||||
02/18/21 | 05/14/21 | $ | i 1.30 |
2022 Form 10-Q | | 17 |
(in millions) | Foreign
currency translation adjustments | Net investment hedging activities | Pension and post-employment benefits | Cash flow hedging activities | Total | ||||||||||||||||||||||||||||||
Balance as of December 31, 2021 | $ | ( i 570) | $ | ( i 91) | $ | ( i 2,546) | $ | i 308 | $ | ( i 2,899) | |||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications | ( i 1,054) | i 696 | ( i 11) | i 45 | ( i 324) | ||||||||||||||||||||||||||||||
Net losses (gains) reclassified from accumulated other comprehensive loss | i — | ( i 30) | i 87 | ( i 30) | i 27 | ||||||||||||||||||||||||||||||
Net current-period other comprehensive income (loss) | ( i 1,054) | i 666 | i 76 | i 15 | ( i 297) | ||||||||||||||||||||||||||||||
Balance as of June 30, 2022 | $ | ( i 1,624) | $ | i 575 | $ | ( i 2,470) | $ | i 323 | $ | ( i 3,196) |
(in millions) | Foreign
currency translation adjustments | Net investment hedging activities | Pension and post-employment benefits | Cash flow hedging activities | Total | ||||||||||||||||||||||||||||||
Balance as of December 31, 2020 | $ | i 583 | $ | ( i 790) | $ | ( i 3,067) | $ | i 157 | $ | ( i 3,117) | |||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications | ( i 433) | i 267 | i 16 | i 27 | ( i 123) | ||||||||||||||||||||||||||||||
Net losses (gains) reclassified from accumulated other comprehensive loss | i — | ( i 7) | i 113 | i 31 | i 137 | ||||||||||||||||||||||||||||||
Net current-period other comprehensive income (loss) | ( i 433) | i 260 | i 129 | i 58 | i 14 | ||||||||||||||||||||||||||||||
Balance as of June 30, 2021 | $ | i 150 | $ | ( i 530) | $ | ( i 2,938) | $ | i 215 | $ | ( i 3,103) |
2022 Form 10-Q | | 18 |
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
(in millions) (brackets denote gains) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net investment hedging activities | |||||||||||||||||||||||
Gains on derivative amount excluded from effectiveness testing(a) | $ | ( i 24) | $ | ( i 5) | $ | ( i 38) | $ | ( i 9) | |||||||||||||||
Tax expense | i 6 | i 1 | i 8 | i 2 | |||||||||||||||||||
Total reclassifications, net of tax | $ | ( i 18) | $ | ( i 4) | $ | ( i 30) | $ | ( i 7) | |||||||||||||||
Pension and post-employment benefits | |||||||||||||||||||||||
Amortization of actuarial losses and other(b) | $ | i 56 | $ | i 74 | $ | i 111 | $ | i 143 | |||||||||||||||
Tax benefit | ( i 12) | ( i 16) | ( i 24) | ( i 30) | |||||||||||||||||||
Total reclassifications, net of tax | $ | i 44 | $ | i 58 | $ | i 87 | $ | i 113 | |||||||||||||||
Cash flow hedging activities | |||||||||||||||||||||||
Losses (gains) on foreign currency forward exchange contracts(c) | $ | ( i 18) | $ | i 22 | $ | ( i 26) | $ | i 34 | |||||||||||||||
Gains
on treasury rate lock agreements(a) | ( i 6) | ( i 6) | ( i 12) | ( i 12) | |||||||||||||||||||
Losses
on interest rate swap contracts(a) | i 1 | i 7 | i 3 | i 14 | |||||||||||||||||||
Tax expense (benefit) | i 4 | ( i 3) | i 5 | ( i 5) | |||||||||||||||||||
Total reclassifications, net of tax | $ | ( i 19) | $ | i 20 | $ | ( i 30) | $ | i 31 |
2022
Form 10-Q | | 19 |
2022 Form 10-Q | | 20 |
2022
Form 10-Q | | 21 |
2022 Form 10-Q | | 22 |
Three months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Immunology | ||||||||||||||||||||||||||
Humira | United States | $ | i 4,664 | $ | i 4,257 | $ | i 8,657 | $ | i 8,164 | |||||||||||||||||
International | i 699 | i 811 | i 1,442 | i 1,771 | ||||||||||||||||||||||
Total | $ | i 5,363 | $ | i 5,068 | $ | i 10,099 | $ | i 9,935 | ||||||||||||||||||
Skyrizi | United States | $ | i 1,079 | $ | i 565 | $ | i 1,860 | $ | i 1,046 | |||||||||||||||||
International | i 173 | i 109 | i 332 | i 202 | ||||||||||||||||||||||
Total | $ | i 1,252 | $ | i 674 | $ | i 2,192 | $ | i 1,248 | ||||||||||||||||||
Rinvoq | United States | $ | i 412 | $ | i 296 | $ | i 723 | $ | i 541 | |||||||||||||||||
International | i 180 | i 82 | i 334 | i 140 | ||||||||||||||||||||||
Total | $ | i 592 | $ | i 378 | $ | i 1,057 | $ | i 681 | ||||||||||||||||||
Hematologic Oncology | ||||||||||||||||||||||||||
Imbruvica | United States | $ | i 862 | $ | i 1,099 | $ | i 1,736 | $ | i 2,098 | |||||||||||||||||
Collaboration revenues | i 283 | i 282 | i 582 | i 551 | ||||||||||||||||||||||
Total | $ | i 1,145 | $ | i 1,381 | $ | i 2,318 | $ | i 2,649 | ||||||||||||||||||
Venclexta | United States | $ | i 253 | $ | i 223 | $ | i 481 | $ | i 448 | |||||||||||||||||
International | i 252 | i 212 | i 497 | i 392 | ||||||||||||||||||||||
Total | $ | i 505 | $ | i 435 | $ | i 978 | $ | i 840 | ||||||||||||||||||
Aesthetics | ||||||||||||||||||||||||||
Botox Cosmetic | United States | $ | i 449 | $ | i 366 | $ | i 862 | $ | i 671 | |||||||||||||||||
International | i 246 | i 218 | i 474 | i 390 | ||||||||||||||||||||||
Total | $ | i 695 | $ | i 584 | $ | i 1,336 | $ | i 1,061 | ||||||||||||||||||
Juvederm Collection | United States | $ | i 147 | $ | i 196 | $ | i 295 | $ | i 319 | |||||||||||||||||
International | i 197 | i 232 | i 459 | i 430 | ||||||||||||||||||||||
Total | $ | i 344 | $ | i 428 | $ | i 754 | $ | i 749 | ||||||||||||||||||
Other Aesthetics | United States | $ | i 287 | $ | i 363 | $ | i 572 | $ | i 663 | |||||||||||||||||
International | i 45 | i 59 | i 83 | i 102 | ||||||||||||||||||||||
Total | $ | i 332 | $ | i 422 | $ | i 655 | $ | i 765 | ||||||||||||||||||
Neuroscience | ||||||||||||||||||||||||||
Botox Therapeutic | United States | $ | i 557 | $ | i 488 | $ | i 1,057 | $ | i 917 | |||||||||||||||||
International | i 121 | i 115 | i 235 | i 218 | ||||||||||||||||||||||
Total | $ | i 678 | $ | i 603 | $ | i 1,292 | $ | i 1,135 | ||||||||||||||||||
Vraylar
| United States | $ | i 492 | $ | i 432 | $ | i 919 | $ | i 778 | |||||||||||||||||
Duodopa | United States | $ | i 26 | $ | i 25 | $ | i 50 | $ | i 50 | |||||||||||||||||
International | i 94 | i 102 | i 191 | i 206 | ||||||||||||||||||||||
Total | $ | i 120 | $ | i 127 | $ | i 241 | $ | i 256 | ||||||||||||||||||
Ubrelvy | United States | $ | i 185 | $ | i 126 | $ | i 323 | $ | i 207 | |||||||||||||||||
Qulipta | United States | $ | i 33 | $ | i — | $ | i 44 | $ | i — | |||||||||||||||||
Other Neuroscience | United States | $ | i 145 | $ | i 167 | $ | i 318 | $ | i 323 | |||||||||||||||||
International | i 5 | i 4 | i 9 | i 8 | ||||||||||||||||||||||
Total | $ | i 150 | $ | i 171 | $ | i 327 | $ | i 331 |
2022
Form 10-Q | | 23 |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Eye Care | ||||||||||||||||||||||||||
Lumigan/Ganfort | United States | $ | i 60 | $ | i 72 | $ | i 127 | $ | i 138 | |||||||||||||||||
International | i 70 | i 77 | i 143 | i 154 | ||||||||||||||||||||||
Total | $ | i 130 | $ | i 149 | $ | i 270 | $ | i 292 | ||||||||||||||||||
Alphagan/Combigan | United States | $ | i 54 | $ | i 102 | $ | i 124 | $ | i 182 | |||||||||||||||||
International | i 38 | i 40 | i 75 | i 78 | ||||||||||||||||||||||
Total | $ | i 92 | $ | i 142 | $ | i 199 | $ | i 260 | ||||||||||||||||||
Restasis | United States | $ | i 151 | $ | i 312 | $ | i 386 | $ | i 579 | |||||||||||||||||
International | i 17 | i 15 | i 28 | i 28 | ||||||||||||||||||||||
Total | $ | i 168 | $ | i 327 | $ | i 414 | $ | i 607 | ||||||||||||||||||
Other Eye Care | United States | $ | i 142 | $ | i 130 | $ | i 266 | $ | i 247 | |||||||||||||||||
International | i 185 | i 171 | i 339 | i 330 | ||||||||||||||||||||||
Total | $ | i 327 | $ | i 301 | $ | i 605 | $ | i 577 | ||||||||||||||||||
Other Key Products | ||||||||||||||||||||||||||
Mavyret | United States | $ | i 203 | $ | i 204 | $ | i 372 | $ | i 374 | |||||||||||||||||
International | i 195 | i 238 | i 406 | i 483 | ||||||||||||||||||||||
Total | $ | i 398 | $ | i 442 | $ | i 778 | $ | i 857 | ||||||||||||||||||
Creon | United States | $ | i 318 | $ | i 280 | $ | i 605 | $ | i 554 | |||||||||||||||||
Linzess/Constella | United States | $ | i 247 | $ | i 260 | $ | i 480 | $ | i 475 | |||||||||||||||||
International | i 8 | i 8 | i 15 | i 15 | ||||||||||||||||||||||
Total | $ | i 255 | $ | i 268 | $ | i 495 | $ | i 490 | ||||||||||||||||||
All other | $ | i 1,009 | $ | i 1,221 | $ | i 2,220 | $ | i 2,697 | ||||||||||||||||||
Total net revenues | $ | i 14,583 | $ | i 13,959 | $ | i 28,121 | $ | i 26,969 |
2022
Form 10-Q | | 24 |
2022 Form 10-Q | | 25 |
2022 Form 10-Q | | 26 |
2022
Form 10-Q | | 27 |
2022
Form 10-Q | | 28 |
Three
months ended June 30, | Percent change | Six months ended June 30, | Percent change | |||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | |||||||||||||||||||||||||||||||||||||||||||||||
(dollars
in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
United States | $ | 11,410 | $ | 10,804 | 5.6 | % | 5.6 | % | $ | 21,758 | $ | 20,554 | 5.9 | % | 5.9 | % | ||||||||||||||||||||||||||||||||||
International | 3,173 | 3,155 | 0.6 | % | 7.6 | % | 6,363 | 6,415 | (0.8) | % | 5.3 | % | ||||||||||||||||||||||||||||||||||||||
Net
revenues | $ | 14,583 | $ | 13,959 | 4.5 | % | 6.1 | % | $ | 28,121 | $ | 26,969 | 4.3 | % | 5.7 | % |
2022
Form 10-Q | | 29 |
Three
months ended June 30, | Percent change | Six months ended June 30, | Percent change | ||||||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | ||||||||||||||||||||||||||||||||||||||||||||||||||
(dollars
in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||
Immunology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Humira | United States | $ | 4,664 | $ | 4,257 | 9.6 | % | 9.6 | % | $ | 8,657 | $ | 8,164 | 6.0 | % | 6.0 | % | ||||||||||||||||||||||||||||||||||||
International | 699 | 811 | (13.8) | % | (7.3) | % | 1,442 | 1,771 | (18.6) | % | (13.1) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 5,363 | $ | 5,068 | 5.8 | % | 6.8 | % | $ | 10,099 | $ | 9,935 | 1.7 | % | 2.7 | % | |||||||||||||||||||||||||||||||||||||
Skyrizi | United States | $ | 1,079 | $ | 565 | 91.1 | % | 91.1 | % | $ | 1,860 | $ | 1,046 | 77.8 | % | 77.8 | % | ||||||||||||||||||||||||||||||||||||
International | 173 | 109 | 59.1 | % | 73.9 | % | 332 | 202 | 64.7 | % | 78.1 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 1,252 | $ | 674 | 85.9 | % | 88.3 | % | $ | 2,192 | $ | 1,248 | 75.7 | % | 77.9 | % | |||||||||||||||||||||||||||||||||||||
Rinvoq | United States | $ | 412 | $ | 296 | 39.4 | % | 39.4 | % | $ | 723 | $ | 541 | 33.7 | % | 33.7 | % | ||||||||||||||||||||||||||||||||||||
International | 180 | 82 | >100.0 % | >100.0 % | 334 | 140 | >100.0 % | >100.0 % | |||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 592 | $ | 378 | 56.3 | % | 60.7 | % | $ | 1,057 | $ | 681 | 55.1 | % | 59.2 | % | |||||||||||||||||||||||||||||||||||||
Hematologic Oncology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Imbruvica | United States | $ | 862 | $ | 1,099 | (21.6) | % | (21.6) | % | $ | 1,736 | $ | 2,098 | (17.2) | % | (17.2) | % | ||||||||||||||||||||||||||||||||||||
Collaboration revenues | 283 | 282 | 0.5 | % | 0.5 | % | 582 | 551 | 5.6 | % | 5.6 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 1,145 | $ | 1,381 | (17.1) | % | (17.1) | % | $ | 2,318 | $ | 2,649 | (12.5) | % | (12.5) | % | |||||||||||||||||||||||||||||||||||||
Venclexta | United States | $ | 253 | $ | 223 | 13.4 | % | 13.4 | % | $ | 481 | $ | 448 | 7.5 | % | 7.5 | % | ||||||||||||||||||||||||||||||||||||
International | 252 | 212 | 19.1 | % | 29.3 | % | 497 | 392 | 26.8 | % | 36.7 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 505 | $ | 435 | 16.2 | % | 21.2 | % | $ | 978 | $ | 840 | 16.5 | % | 21.1 | % | |||||||||||||||||||||||||||||||||||||
Aesthetics | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Botox Cosmetic | United States | $ | 449 | $ | 366 | 22.4 | % | 22.4 | % | $ | 862 | $ | 671 | 28.3 | % | 28.3 | % | ||||||||||||||||||||||||||||||||||||
International | 246 | 218 | 12.9 | % | 19.2 | % | 474 | 390 | 21.5 | % | 27.7 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 695 | $ | 584 | 18.9 | % | 21.2 | % | $ | 1,336 | $ | 1,061 | 25.8 | % | 28.1 | % | |||||||||||||||||||||||||||||||||||||
Juvederm Collection | United States | $ | 147 | $ | 196 | (24.9) | % | (24.9) | % | $ | 295 | $ | 319 | (7.5) | % | (7.5) | % | ||||||||||||||||||||||||||||||||||||
International | 197 | 232 | (15.0) | % | (8.1) | % | 459 | 430 | 6.7 | % | 13.0 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 344 | $ | 428 | (19.5) | % | (15.7) | % | $ | 754 | $ | 749 | 0.7 | % | 4.3 | % | |||||||||||||||||||||||||||||||||||||
Other Aesthetics | United States | $ | 287 | $ | 363 | (20.9) | % | (20.9) | % | $ | 572 | $ | 663 | (13.6) | % | (13.6) | % | ||||||||||||||||||||||||||||||||||||
International | 45 | 59 | (24.4) | % | (20.2) | % | 83 | 102 | (18.3) | % | (14.3) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 332 | $ | 422 | (21.4) | % | (20.8) | % | $ | 655 | $ | 765 | (14.2) | % | (13.7) | % | |||||||||||||||||||||||||||||||||||||
Neuroscience | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Botox Therapeutic | United States | $ | 557 | $ | 488 | 14.2 | % | 14.2 | % | $ | 1,057 | $ | 917 | 15.3 | % | 15.3 | % | ||||||||||||||||||||||||||||||||||||
International | 121 | 115 | 5.6 | % | 15.6 | % | 235 | 218 | 8.0 | % | 16.3 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 678 | $ | 603 | 12.6 | % | 14.5 | % | $ | 1,292 | $ | 1,135 | 13.9 | % | 15.5 | % | |||||||||||||||||||||||||||||||||||||
Vraylar | United States | $ | 492 | $ | 432 | 13.9 | % | 13.9 | % | $ | 919 | $ | 778 | 18.1 | % | 18.1 | % | ||||||||||||||||||||||||||||||||||||
Duodopa | United States | $ | 26 | $ | 25 | 3.2 | % | 3.2 | % | $ | 50 | $ | 50 | (1.2) | % | (1.2) | % | ||||||||||||||||||||||||||||||||||||
International | 94 | 102 | (7.4) | % | 2.2 | % | 191 | 206 | (7.2) | % | 1.3 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 120 | $ | 127 | (5.4) | % | 2.3 | % | $ | 241 | $ | 256 | (6.0) | % | 0.8 | % | |||||||||||||||||||||||||||||||||||||
Ubrelvy | United States | $ | 185 | $ | 126 | 47.6 | % | 47.6 | % | $ | 323 | $ | 207 | 56.4 | % | 56.4 | % | ||||||||||||||||||||||||||||||||||||
Qulipta | United States | $ | 33 | $ | — | n/m | n/m | $ | 44 | $ | — | n/m | n/m | ||||||||||||||||||||||||||||||||||||||||
Other Neuroscience | United States | $ | 145 | $ | 167 | (13.6) | % | (13.6) | % | $ | 318 | $ | 323 | (1.7) | % | (1.7) | % | ||||||||||||||||||||||||||||||||||||
International | 5 | 4 | 9.6 | % | 12.9 | % | 9 | 8 | 10.4 | % | 12.6 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 150 | $ | 171 | (12.9) | % | (12.8) | % | $ | 327 | $ | 331 | (1.4) | % | (1.3) | % |
2022
Form 10-Q | | 30 |
Three
months ended June 30, | Percent change | Six months ended June 30, | Percent change | ||||||||||||||||||||||||||||||||||||||||||||||||||
At actual currency rates | At constant currency rates | At actual currency rates | At constant currency rates | ||||||||||||||||||||||||||||||||||||||||||||||||||
(dollars
in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||
Eye Care | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Lumigan/Ganfort | United States | $ | 60 | $ | 72 | (17.4) | % | (17.4) | % | $ | 127 | $ | 138 | (8.3) | % | (8.3) | % | ||||||||||||||||||||||||||||||||||||
International | 70 | 77 | (8.1) | % | (0.9) | % | 143 | 154 | (6.9) | % | (0.1) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 130 | $ | 149 | (12.5) | % | (8.7) | % | $ | 270 | $ | 292 | (7.5) | % | (3.9) | % | |||||||||||||||||||||||||||||||||||||
Alphagan/Combigan | United States | $ | 54 | $ | 102 | (48.5) | % | (48.5) | % | $ | 124 | $ | 182 | (32.3) | % | (32.3) | % | ||||||||||||||||||||||||||||||||||||
International | 38 | 40 | (2.3) | % | 6.6 | % | 75 | 78 | (3.1) | % | 6.0 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 92 | $ | 142 | (35.6) | % | (33.1) | % | $ | 199 | $ | 260 | (23.6) | % | (20.9) | % | |||||||||||||||||||||||||||||||||||||
Restasis | United States | $ | 151 | $ | 312 | (51.5) | % | (51.5) | % | $ | 386 | $ | 579 | (33.2) | % | (33.2) | % | ||||||||||||||||||||||||||||||||||||
International | 17 | 15 | 14.9 | % | 24.2 | % | 28 | 28 | (0.2) | % | 14.0 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 168 | $ | 327 | (48.4) | % | (48.0) | % | $ | 414 | $ | 607 | (31.7) | % | (31.0) | % | |||||||||||||||||||||||||||||||||||||
Other Eye Care | United States | $ | 142 | $ | 130 | 9.7 | % | 9.7 | % | $ | 266 | $ | 247 | 7.7 | % | 7.7 | % | ||||||||||||||||||||||||||||||||||||
International | 185 | 171 | 7.4 | % | 16.0 | % | 339 | 330 | 2.6 | % | 10.5 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 327 | $ | 301 | 8.4 | % | 13.2 | % | $ | 605 | $ | 577 | 4.8 | % | 9.3 | % | |||||||||||||||||||||||||||||||||||||
Other Key Products | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Mavyret | United States | $ | 203 | $ | 204 | 0.2 | % | 0.2 | % | $ | 372 | $ | 374 | (0.4) | % | (0.4) | % | ||||||||||||||||||||||||||||||||||||
International | 195 | 238 | (18.0) | % | (9.8) | % | 406 | 483 | (15.9) | % | (8.4) | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 398 | $ | 442 | (9.7) | % | (5.3) | % | $ | 778 | $ | 857 | (9.1) | % | (4.9) | % | |||||||||||||||||||||||||||||||||||||
Creon | United States | $ | 318 | $ | 280 | 13.6 | % | 13.6 | % | $ | 605 | $ | 554 | 9.2 | % | 9.2 | % | ||||||||||||||||||||||||||||||||||||
Linzess/Constella | United States | $ | 247 | $ | 260 | (4.2) | % | (4.2) | % | $ | 480 | $ | 475 | 1.3 | % | 1.3 | % | ||||||||||||||||||||||||||||||||||||
International | 8 | 8 | (12.5) | % | (7.8) | % | 15 | 15 | (3.8) | % | 0.7 | % | |||||||||||||||||||||||||||||||||||||||||
Total | $ | 255 | $ | 268 | (4.5) | % | (4.4) | % | $ | 495 | $ | 490 | 1.1 | % | 1.2 | % | |||||||||||||||||||||||||||||||||||||
All other | $ | 1,009 | $ | 1,221 | (17.5) | % | (16.4) | % | $ | 2,220 | $ | 2,697 | (17.8) | % | (16.8) | % | |||||||||||||||||||||||||||||||||||||
Total net revenues | $ | 14,583 | $ | 13,959 | 4.5 | % | 6.1 | % | $ | 28,121 | $ | 26,969 | 4.3 | % | 5.7 | % |
2022 Form 10-Q | | 31 |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Gross margin | $ | 10,413 | $ | 9,436 | 10 | % | $ | 19,899 | $ | 18,233 | 9 | % | ||||||||||||||||||||||||||
as a % of net revenues | 71 | % | 68 | % | 71 | % | 68 | % |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Selling, general and administrative | $ | 5,412 | $ | 3,164 | 71 | % | $ | 8,539 | $ | 6,006 | 42 | % | ||||||||||||||||||||||||||
as a % of net revenues | 37 | % | 23 | % | 30 | % | 22 | % |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||||||||||||||
(dollars in millions) | 2022 | 2021 | % change | 2022 | 2021 | % change | ||||||||||||||||||||||||||||||||
Research and development | $ | 1,609 | $ | 1,767 | (9) | % | $ | 3,106 | $ | 3,434 | (10) | % | ||||||||||||||||||||||||||
as a % of net revenues | 11 | % | 13 | % | 11 | % | 13 | % | ||||||||||||||||||||||||||||||
Acquired IPR&D and milestones | $ | 269 | $ | 132 | >100% | $ | 414 | $ | 317 | 31 | % |
2022 Form 10-Q | | 32 |
Three
months ended June 30, | Six months ended June 30, | |||||||||||||||||||||||||
(in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||||||||||||
Interest expense | $ | 556 | $ | 615 | $ | 1,104 | $ | 1,247 | ||||||||||||||||||
Interest income | (24) | (9) | (33) | (19) | ||||||||||||||||||||||
Interest expense, net | $ | 532 | $ | 606 | $ | 1,071 | $ | 1,228 | ||||||||||||||||||
Net foreign exchange loss | $ | 47 | $ | 14 | $ | 72 | $ | 23 | ||||||||||||||||||
Other expense, net | 1,533 | 2,658 | 757 | 2,263 |
2022
Form 10-Q | | 33 |
Six months ended June 30, | |||||||||||
(in millions) | 2022 | 2021 | |||||||||
Cash flows provided by (used in): | |||||||||||
Operating activities | $ | 9,913 | $ | 9,767 | |||||||
Investing activities | (1,461) | (584) | |||||||||
Financing activities | (9,651) | (9,058) |
2022 Form 10-Q | | 34 |
2022
Form 10-Q | | 35 |
2022
Form 10-Q | | 36 |
Period | (a) Total
Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | ||||||||||||||||||||||
April 1, 2022 - April 30, 2022 | 28,809 | (1) | $162.39 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
May 1, 2022 - May 31, 2022 | 839 | (1) | $151.92 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
June 1, 2022 - June 30, 2022 | 989 | (1) | $146.78 | (1) | — | $1,393,714,917 | ||||||||||||||||||||
Total | 30,637 | (1) | $161.60 | (1) | — | $1,393,714,917 |
2022 Form 10-Q | | 37 |
Exhibit No. | Exhibit Description | |||||||
101 | The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 4, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash
Flows; and (vi) the Notes to Condensed Consolidated Financial Statements. | |||||||
104 | Cover Page Interactive Data File (the cover page from the AbbVie Inc. Quarterly Report on Form 10-Q formatted as Inline XBRL and contained in Exhibit 101). |
2022
Form 10-Q | | 38 |
ABBVIE INC. | ||||||||
By: | /s/ Scott T. Reents | |||||||
Scott T. Reents | ||||||||
Senior Vice President, | ||||||||
Chief Financial Officer (Principal Financial Officer) |
2022 Form 10-Q | | 39 |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
8/15/22 | ||||
Filed on: | 8/4/22 | |||
7/27/22 | ||||
7/15/22 | ||||
For Period end: | 6/30/22 | 4 | ||
6/23/22 | 11-K, 8-K | |||
6/1/22 | ||||
5/31/22 | SD | |||
5/1/22 | ||||
4/30/22 | ||||
4/1/22 | ||||
3/31/22 | 10-Q, 4 | |||
12/31/21 | 10-K, 11-K, 4, SD | |||
8/30/21 | ||||
6/30/21 | 10-Q, 4 | |||
3/31/21 | 10-Q, 4, PX14A6G | |||
12/31/20 | 10-K, 11-K, 4, 8-K, SD | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/17/23 AbbVie Inc. 10-K 12/31/22 120:24M 11/04/22 AbbVie Inc. S-8 11/04/22 4:106K Toppan Merrill/FA |